BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 22717740)

  • 1. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
    Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
    Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.
    Fujiyuki T; Yoneda M; Amagai Y; Obayashi K; Ikeda F; Shoji K; Murakami Y; Sato H; Kai C
    Oncotarget; 2015 Sep; 6(28):24895-903. PubMed ID: 26317644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles virus selectively blind to signaling lymphocyte activity molecule has oncolytic efficacy against nectin-4-expressing pancreatic cancer cells.
    Awano M; Fujiyuki T; Shoji K; Amagai Y; Murakami Y; Furukawa Y; Sato H; Yoneda M; Kai C
    Cancer Sci; 2016 Nov; 107(11):1647-1652. PubMed ID: 27561180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo.
    Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY
    J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of a recombinant measles virus against canine lung cancer cells.
    Tamura K; Fujiyuki T; Moritoh K; Akimoto H; Iizuka K; Sato H; Asano K; Yoneda M; Kai C
    Sci Rep; 2023 Oct; 13(1):18168. PubMed ID: 37875555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.
    Paraskevakou G; Allen C; Nakamura T; Zollman P; James CD; Peng KW; Schroeder M; Russell SJ; Galanis E
    Mol Ther; 2007 Apr; 15(4):677-86. PubMed ID: 17299404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells.
    Amagai Y; Fujiyuki T; Yoneda M; Shoji K; Furukawa Y; Sato H; Kai C
    Sci Rep; 2016 Apr; 6():24572. PubMed ID: 27090874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
    Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells.
    Iizuka K; Shoji K; Fujiyuki T; Moritoh K; Tamura K; Yoshida A; Sato H; Yoneda M; Asano K; Kai C
    Res Vet Sci; 2020 Dec; 133():313-317. PubMed ID: 33183781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of new therapy for canine mammary cancer with recombinant measles virus.
    Shoji K; Yoneda M; Fujiyuki T; Amagai Y; Tanaka A; Matsuda A; Ogihara K; Naya Y; Ikeda F; Matsuda H; Sato H; Kai C
    Mol Ther Oncolytics; 2016; 3():15022. PubMed ID: 27119113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response elicited in the tumor microenvironment upon rMV-SLAMblind cancer virotherapy.
    Moritoh K; Shoji K; Amagai Y; Fujiyuki T; Sato H; Yoneda M; Kai C
    Cancer Sci; 2023 May; 114(5):2158-2168. PubMed ID: 36715555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
    McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E
    Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered interaction of the matrix protein with the cytoplasmic tail of hemagglutinin modulates measles virus growth by affecting virus assembly and cell-cell fusion.
    Tahara M; Takeda M; Yanagi Y
    J Virol; 2007 Jul; 81(13):6827-36. PubMed ID: 17442724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor.
    Ono N; Tatsuo H; Hidaka Y; Aoki T; Minagawa H; Yanagi Y
    J Virol; 2001 May; 75(9):4399-401. PubMed ID: 11287589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains.
    Lv Y; Zhou D; Hao XQ; Zhu MY; Zhang CD; Zhou DM; Wang JH; Liu RX; Wang YL; Gu WZ; Shen HQ; Chen X; Zhao ZY
    Cancer Lett; 2019 Sep; 460():108-118. PubMed ID: 31226409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple amino acid substitutions in hemagglutinin are necessary for wild-type measles virus to acquire the ability to use receptor CD46 efficiently.
    Tahara M; Takeda M; Seki F; Hashiguchi T; Yanagi Y
    J Virol; 2007 Mar; 81(6):2564-72. PubMed ID: 17182683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.
    Miest TS; Frenzke M; Cattaneo R
    Mol Ther; 2013 Nov; 21(11):2019-31. PubMed ID: 23913184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
    Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
    Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ablation of nectin4 binding compromises CD46 usage by a hybrid vesicular stomatitis virus/measles virus.
    Liu YP; Russell SP; Ayala-Breton C; Russell SJ; Peng KW
    J Virol; 2014 Feb; 88(4):2195-204. PubMed ID: 24335299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.